Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18:A multimodal anticancer interface marked by specific modulation in serum cytokines

Clinical Cancer Research

Volumn 15, Issue 7, 2009, Pages 2323-2334

  Khatri, Aparajita ^a   Husaini, Yasmin ^b   Ow, Kim ^a   Chapman, Jane ^a   Russell, Pamela J ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYTOSINE DEAMINASE; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 4; MONOCYTE CHEMOTACTIC PROTEIN 1; URACIL PHOSPHORIBOSYLTRANSFERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; GENE DIRECTED ENZYME PRODRUG THERAPY; IMMUNE RESPONSE; IMMUNOSTIMULATION; LUNG DEPOSIT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; TH1 CELL; TH2 CELL; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; CYTOKINES; CYTOSINE DEAMINASE; FLUCYTOSINE; INTERLEUKIN-12; INTERLEUKIN-18; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; MICE, INBRED C57BL; PENTOSYLTRANSFERASES; PRODRUGS; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TH2 CELLS;

EID: 65349136400     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2039     Document Type: Article

References (51)

1. Freeman SM, Ramesh R, Marrogi AJ. Immune system in suicide-gene therapy. Lancet 1997;349:2-3.
2. Chen SH, Chen XH, WangY, et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci U S A 1995;92:2577-81.
3. Cao X, Huang X, Ju DW, et al. Enhanced antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through stem cell factor/granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Gene Ther 2000;7:177-86.
4. Hwang KS, ChoWK,YooJ, et al. Adenovirus-mediat- ed interleukin-12 gene transfer combined with cyto- sine deaminase followed by 5-fluo ro cy tosine treatment exerts potent antitumor activity in Renca tumor-bearing mice. BMC Cancer 2005;5:51.
5. Nakamori M, Iwahashi M, Ueda K, et al. Dose of ad- enoviral vectors expressing interleukin-2 plays an important role in combined gene therapy with cytosine deaminase/5-fluorocytosine: preclinical consideration. Jpn J Cancer Res 2002;93:706-15.
6. Toda M, Martuza RL, Rabkin SD. Combination sui- cide/cytokine gene the rapy as adjuvants to a defective herpes simplex virus-based cancer vaccine. GeneTher 2001;8:332-9.
7. FujitaT, Teh BS,TimmeTL, et al. Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. Int J Radiat Oncol Biol Phys 2006;65:84-90.
8. Tiraby M, Cazaux C, Baron M, et al. Concomitant expression of E. coli cytosine deaminase and uracil phosphoribosyltransferase improves the cytotoxicity of 5-fluorocytosine. FEMS Microbiol Lett 1998;167: 41 -9.
9. Kanai F, Kawakami T, Hamada H, et al. Adenovirus- mediated transduction of Escherichia coli uracil phosphoribosyl transferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res 1998;58:1946-51.
10. Richard C, Duivenvoorden W, Bourbeau D, et al. Sensitivity of 5-fluorouracil-resistant cancer cells to adenovirus suicide gene therapy. Cancer Gene Ther 2007;14:57-65.
11. Khatri A, Zhang B, Doherty E, et al. Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice. J Gene Med 2006;8:1086-96.
12. Cao X, Ju DW, Tao Q, et al. Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice. GeneTher 1998;5:1130-6.
13. Nanni P, De Giovanni C, Nicoletti G, et al. The immune response elicited by mammary adenocarcinoma cells transduced with interferon-γ and cytosine deaminase genes cures lung metastases by parental cells. Hum GeneTher1998;9:217-24.
14. Ju DW,Cao X, Tao Q,et al. Augmentation of anti- tumor effect of adenovirus-mediated CD suicide gene therapy by cotransfer of interleukin 2 gene in melanoma-bearing mice. Chin Med J (Engl) 1999; 112:162-5.
15. Sun W, Tang Z, Wei D, Tang Y, Chen S. [Combined gene therapy for murine liver cancer with interleukin- 18 and cytosine deaminase genes]. Zhonghua Gan Zang Bing Za Zhi 2001;9:300-2.
16. Melero I, MazzoliniG,Narvaiza I,et al. IL-12gene therapy for cancer: in synergy with other immuno- therapies.Trends Immunol 2001;22:113-5.
17. Podhajcer OL, Lopez MV, Mazzolini G. Cytokine gene transfer for cancer therapy. Cytokine Growth Factor Rev 2007;18:183-94.
18. Li Q, CarrAL, Donald EJ, et al. Synergistic effects of IL-12andIL-18inskewingtumor-reactiveT-cell responses towards a type 1 pattern. Cancer Res 2005;65:1063-70.
19. Tatsumi T, Huang J, Gooding WE, et al. Intratu- moral delivery of dendriticcells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res 2003;63:6378-86.
20. Eaton AD, Xu D, Garside P. Administration of exogenous interleukin-18 and interleukin-12 prevents the induction of oral tolerance. Immunology 2003;108: 196-203.
21. Zhang JH, Wei HM,Tian ZG. Analysis tissue expression of IFN-γ in IL-12 and/or IL-18 gene ablated naive mice. Cell Mol Immunol 2005;2:68-72.
22. Voeks DJ, Martiniello-Wilks R, Russell PJ. Derivation of MPR and TRAMP models of prostate cancer and prostate cancer metastasis for evaluation of ther- apeutic strategies. Urol Oncol 2002;7:111 -8.
23. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y Cytokines in cancer immunity and immunotherapy. Immunol Rev 2004;202:275-93.
24. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Phar- macother 2004;58:24-38.
25. Thompson TC, Southgate J, Kitchener G, Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989;56: 917-30.
26. Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 1998;17: 279-84.
27. Ju DW,YangY,Tao Q, etal. Interleukin-18 genetrans- fer increases antitumor effects of suicide gene therapy through efficient induction of antitumor immunity. GeneTher 2000;7:1672-9.
28. Jia SF, Duan X, Worth LL, Guan H, Kleinerman ES. Intratumor murine interleukin-12 gene therapy suppressed the growth of local and distant Ewing's sarcoma. Cancer GeneTher 2006;13:948-57.
29. Sgadari C, Angiolillo AL,Tosato G. Inhibition of an- giogenesis by interleukin-12 is mediated by the inter- feron-inducible protein 10. Blood 1996;87:3877-82.
30. Nagai H, Hara I, HorikawaT, et al. Gene transfer of secreted-typemodified interleukin-18 geneto B16F10 melanoma cells suppresses in vivo tumor growth through inhibition of tumor vessel formation. J Invest Dermatol 2002;119:541 -8.
31. Hildesheim A, Ryan RL, Rinehart E, et al. Simultaneous measurement of several cytokines using small volumes of biospecimens. Cancer Epidemiol Biomarkers Prev 2002;11:1477-84.
32. Yoshie O, Fujisawa R, NakayamaT, et al. Frequent expression of CCR4 in adultT-cell leukemia and hu- manT-cell leukemia virus type 1-transformed Tcells. Blood 2002;99:1505-11.
33. Gu L,Tseng S, Horner RM, et al. Control of TH2 polarization by the chemokine monocyte chemoattrac- tant protein-1. Nature 2000;404:407-11.
34. Tomova R, Pomakov J, Jacobs JJ, et al. Changes in cytokine profile during local IL-2 therapy in cancer patients. Anticancer Res 2006;26:2037-47.
35. Macgregor JN, Li Q, Chang AE, et al. Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-celladop- tive immunotherapy for murine leukemia independent of IL-18 or IFN-γ but requires perforin. Cancer Res 2006;66:4913-21.
36. Drevs J, Fakler J, Eisele S, et al. Antiangiogenicpo- tency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 2004;24: 1759-63.
37. Hall SJ, Sanford MA, Atkinson G, Chen SH. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopicmouse model of prostate cancer. Cancer Res 1998;58:3221 -5.
38. Frost P, Caliliw R, Belldegrun A, Bonavida B. Immu- nosensitization of resistant human tumor cellstocyto- toxicity by tumor infiltrating lymphocytes. Int J Oncol 2003;22:431 -7.
39. Frost P, Ng CP, Belldegrun A, Bonavida B. Immuno- sensitization of prostate carcinoma cell lines for lymphocytes (CTL,TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. Cell Immunol 1997;180:70-83.
40. Correale P, Aquino A, Giuliani A, et al. Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA- peptide-specific cytotoxic T cells in vitro. Int J Cancer 2003;104:437-45.
41. Correale P, Del Vecchio MT, Di Genova G, et al. 5-Fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-direct- ed polyepitopic peptide vaccine. J Natl Cancer Inst 2005;97:1437-45.
42. Khatri A, Husaini Y, Russell PJ. Murine CTLL-2 cells respond to mIL12: prospects for developing an alternative bioassay for measurement of murine cytokines IL12 and IL18. J Immunol Methods 2007; 326:41 -53.
43. Satoko HIH, Hideaki M, Shoji H, Sadao K. Antitumor effect of simultaneous transfer of interleukin-12 and interleukin-18 genes and its mechanism in a mouse bladder cancer model. Int J Urol 2004;11: 647-52.
44. SakuraiH,Kawabata K,Sakurai F, Nakagawa S, Mizuguchi H. Innate immune response induced by gene delivery vectors. Int J Pharm 2008;354: 9-15.
45. ClericiM,Shearer GM,ClericiE. Cytokine dysregu- lation in invasive cervical carcinoma and other human neoplasias: time to consider theTH1/TH2 paradigm. JNatl Cancer Inst1998;90:261 -3.
46. Becker Y. Molecular immunological approaches to biotherapy of human cancers-a review, hypothesis and implications. Anticancer Res 2006;26:1113-34.
47. Aruga A, Aruga E,Tanigawa K, et al. Type 1 versus type 2 cytokine release by Vβ T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. JImmunol 1997;159:664-73.
48. Yan L, Anderson GM, DeWitte M, Nakada MT. Therapeutic potential of cytokine and chemokine antagonists in cancer therapy. Eur J Cancer 2006; 42:793-802.
49. Loberg RD,Ying C, Craig M, et al. Targeting CCL2 with systemic delivery of neutralizing antibodiesindu- ces prostate cancer tumor regression in vivo.Cancer Res2007;67:9417-24.
50. Berghella AM, Contasta I, Pellegrini P, Del Beato T, Adorno D. Peripheral blood immunological parameters for use as markers of pre-invasive to invasive colorectal cancer. Cancer Biother Radiopharm 2002;17:43-50.
51. Lee SO, Pinder E, Chun JY, et al. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells. Prostate 2008;68: 85-91.